Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient

Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient

Abstract The survival outcomes of the FLAURA trial support osimertinib as the new standard of care for untreated patients harboring activating mutations in the epidermal growth factor receptor (EGFR). Despite the initial response, disease progression invariably occurs. Although uncommon, BRAF V600E...

Full description

Bibliographic Details
Main Authors: Maurício Fernando Silva Almeida Ribeiro, Franciele Hinterholz Knebel, Fabiana Bettoni, Rodrigo Saddi, Karina Perez Sacardo, Felipe Sales Nogueira Amorim Canedo, João Victor Machado Alessi, Andrea Kazumi Shimada, José Flávio Gomes Marin, Anamaria Aranha Camargo, Artur Katz
Format: Article
Language:English
Published: Nature Publishing Group 2021-02-01
Series:npj Precision Oncology
Online Access:https://doi.org/10.1038/s41698-021-00149-4

Internet

https://doi.org/10.1038/s41698-021-00149-4

Similar Items